Evoke Pharma Reports First Quarter 2024 Financial Results
Evoke Pharma reported a strong first quarter for 2024, with net product sales increasing by 114% year-over-year to $1.7 million. The company saw a 70% growth in prescriber numbers compared to Q4 2023 and reaffirmed its $14 million net revenue guidance for 2024. Challenges included a cyberattack and increased co-pay expenses, but the company remains optimistic, leveraging its partnership with ASPN Pharmacies. The first quarter also saw the company raising $8.8 million through a public offering. Net loss was reduced to $1.6 million from $2.2 million in Q1 2023. Cash position stands at $9.7 million, expected to fund operations into Q1 2025.
- 114% year-over-year increase in net product sales to $1.7 million.
- 70% growth in prescriber numbers in Q1 2024 compared to Q4 2023.
- Net revenue guidance for 2024 reaffirmed at $14 million.
- Reduction in net loss to $1.6 million from $2.2 million in Q1 2023.
- Raised $8.8 million through a public offering in Q1 2024.
- Partnership with ASPN Pharmacies expected to enhance service delivery and patient reach.
- Cash and cash equivalents of $9.7 million, funding operations into Q1 2025.
- Increased co-pay expenses due to lower payor reimbursements.
- Cyberattack on the largest U.S. medical claims processor disrupted new patient enrollments and refill adjudications.
- Net loss of $1.6 million in Q1 2024, though reduced from previous year.
- Selling, general, and administrative expenses increased to $3.1 million from $2.8 million in Q1 2023.
- Total operating expenses increased to $3.2 million from $3.0 million in Q1 2023.
Insights
Evoke Pharma has reported substantial growth in multiple key areas, including a notable
Examining the impact of external factors such as the cyberattack on the largest U.S. medical claims processor, the company demonstrated resilience by mitigating these challenges and still achieving a
The improved cash position, bolstered by an
Notably, the company has reduced its net loss from
The reaffirmed revenue guidance of
From a medical perspective, the increasing adoption of GIMOTI® is a strong indicator of its clinical efficacy and market acceptance. The real-world evidence from over 500 patients solidifies the product's standing as an effective treatment for diabetic gastroparesis. This is important as it translates into better healthcare outcomes and supports the continued growth of the medication in the market.
Moreover, the focus on healthcare resource utilization data presented at medical conferences and through KOLs, like Dr. Michael Cline, adds a layer of credibility. The bypassing of the gastrointestinal tract via nasal delivery is a significant advantage for patients with gastroparesis, where oral medications can be less effective due to gastric motility issues. This unique selling point likely contributes to the growing demand and favorable patient experiences noted in the report.
As the company strengthens its pharmacy service partnerships, particularly with ASPN Pharmacies, the patient reach and service delivery are expected to improve, supporting the ongoing adoption and sales growth for GIMOTI®.
The 70% increase in prescriber growth and a 10% rise in medication fills highlight a positive market response to GIMOTI. Such growth rates are impressive and suggest that Evoke Pharma’s marketing and educational efforts are bearing fruit. It is also noteworthy that these results were achieved despite disruptions from the cyberattack and increased co-pay expenses, demonstrating effective strategic adjustments by the company.
The company’s emphasis on promoting GIMOTI through webinars, conferences and real-world data presentations is enhancing its visibility among healthcare providers and patients. This tactic is likely to consolidate its market position and facilitate further growth.
In terms of broader market implications, Evoke Pharma appears to be capitalizing on an unmet need within the gastrointestinal treatment space. The niche focus on gastroparesis could position the company favorably against competitors, provided they continue to address any operational challenges effectively.
Growing sales metrics reaffirms company’s
SOLANA BEACH, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the first quarter ended March 31, 2024, and recent corporate developments.
Matt D’Onofrio, CEO of Evoke Pharma commented, “The results achieved in the first quarter of 2024 reflect continued momentum with the adoption of GIMOTI. The real-world healthcare utilization data, including outcomes from over 500 patients, have consistently supported GIMOTI's efficacy for diabetic gastroparesis treatment compared to oral. Moreover, testimonials from leading physicians and the positive experiences shared by patients underscore the growing demand and trust in GIMOTI.”
“In the first quarter of 2024, our net revenue of approximately
First Quarter 2024 Developments and Recent Highlights:
- Maximizing GIMOTI Awareness Building Efforts through KOLs & Conferences
– Held virtual webinar featuring Michael Cline, DO., Medical Director Gastroparesis Clinic at the Cleveland Clinic in April to discuss compelling healthcare resource utilization data showing improved hospitilization rates, and his view on patient experience with GIMOTI.
– Abstract focused on the healthcare resource utilization data of diabetic gastroparesis care in women using nasal metoclopramide to be presented at Digestive Disease Week (“DDW”) 2024 in Washington D.C. - Transitioned Pharmacy Service Partnership & Initiated First Year of Distribution with ASPN Pharmacies
– Scaling up GIMOTI distribution infrastructure and improving patient outcomes with access to ASPN’s expansive pharmacy network. Initiated pharmacy service agreement with ASPN in November 2023. - Improved Cash Position
– In Q1, the Company raised$8.8M in gross proceeds from a public offering and subsequent exercise of warrants with fundamental, healthcare-oriented institutional investors providing the company runway into the fourth quarter of 2024 with up to an additional$21.8M available if common stock warrants are exercised in full.
"During our recent Key Opinion Leader (KOL) webinar, Dr. Michael Cline from the Cleveland Clinic discussed the limitations of oral metoclopramide for treating gastroparesis, noting its unpredictable effects due to gastric emptying variations. GIMOTI addresses these issues with its nasal delivery system, bypassing the faulty GI track in these patients. Moving forward, we will amplify our promotional efforts for GIMOTI through the insights of our KOLs, real-world data, and conferences such as the upcoming Digestive Disease Week (DDW). Later this month at DDW we will present data on the clinical use of nasal metoclopramide in women with gastroparesis, highlighting its benefits and practical application,” Mr. D’Onofrio concluded.
Fourth Quarter and Full Year 2023 Financial Review and Outlook
For the first quarter of 2024, net product sales were approximately
For the first quarter of 2024, selling, general and administrative expenses were approximately
Total operating expenses for the first quarter of 2023 were approximately
As of March 31, 2024, cash and cash equivalents were approximately
Evoke reiterates its net revenue guidance in 2024 of approximately
About Evoke Pharma, Inc.
Evoke is a specialty pharmaceutical company focused primarily on the development of drugs to treat GI disorders and diseases. The company developed, commercialized and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults.
Diabetic gastroparesis is a GI disorder affecting millions of patients worldwide, in which the stomach takes too long to empty its contents resulting in serious GI symptoms as well as other systemic complications. The gastric delay caused by gastroparesis can compromise absorption of orally administered medications. Prior to FDA approval to commercially market GIMOTI, metoclopramide was only available in oral and injectable formulations and remains the only drug currently approved in the United States to treat gastroparesis.
Visit www.EvokePharma.com for more information.
Follow GIMOTI on Facebook
Follow Evoke Pharma on Facebook
Follow Evoke Pharma on LinkedIn
Follow Evoke Pharma on Twitter
About Gimoti® (metoclopramide) nasal spray
GIMOTI is indicated for the relief of symptoms in adults with acute and recurrent diabetic gastroparesis. Important Safety Information
WARNING: TARDIVE DYSKINESIA
- Metoclopramide can cause tardive dyskinesia (TD), a serious movement disorder that is often irreversible. The risk of developing TD increases with duration of treatment and total cumulative dosage.
- Discontinue GIMOTI in patients who develop signs or symptoms of TD. In some patients, symptoms may lessen or resolve after metoclopramide is stopped.
- Avoid treatment with metoclopramide (all dosage forms and routes of administration) for longer than 12 weeks because of the increased risk of developing TD with longer-term use.
GIMOTI is not recommended for use in:
- Pediatric patients due to the risk of developing tardive dyskinesia (TD) and other extrapyramidal symptoms as well as the risk of methemoglobinemia in neonates.
- Moderate or severe hepatic impairment (Child-Pugh B or C), moderate or severe renal impairment (creatinine clearance less than 60 mL/minute), and patients concurrently using strong CYP2D6 inhibitors due to the risk of increased drug exposure and adverse reactions.
GIMOTI is contraindicated:
- In patients with a history of tardive dyskinesia (TD) or a dystonic reaction to metoclopramide.
- When stimulation of gastrointestinal motility might be dangerous (e.g., in the presence of gastrointestinal hemorrhage mechanical obstruction, or perforation).
- In patients with pheochromocytoma or other catecholamine-releasing paragangliomas. Metoclopramide may cause a hypertensive/pheochromocytoma crisis, probably due to release of catecholamines from the tumor.
- In patients with epilepsy. Metoclopramide may increase the frequency and severity of seizures.
- In patients with hypersensitivity to metoclopramide. Reactions have included laryngeal and glossal angioedema and bronchospasm.
Potential adverse reactions associated with metoclopramide include: Tardive dyskinesia (TD), other extrapyramidal effects (EPS), parkinsonism symptoms, motor restlessness, neuroleptic malignant syndrome (NMS), depression, suicidal ideation and suicide, hypertension, fluid retention, hyperprolactinemia, effects on the ability to drive and operate machinery. Most common adverse reactions (≥
Visit www.fda.gov/medwatch or call 1-800-FDA-1088.
Safe Harbor Statement
Evoke cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negatives of these terms or other similar expressions. These statements are based on the company’s current beliefs and expectations. These forward-looking statements include statements regarding: guidance regarding 2024 net product sales; potential future prescribing trends for GIMOTI based on Evoke’s or EVERSANA’s marketing efforts; Evoke’s commercialization plans, including the potential that GIMOTI could become the standard of care for gastroparesis; the potential for additional funds from the exercise of outstanding warrants and Evoke’s expected cash runway. The inclusion of forward-looking statements should not be regarded as a representation by Evoke that any of its plans will be achieved. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Evoke’s business, including, without limitation: Evoke may not be able to achieve its guidance for 2024 including as a result of decreased demand for GIMOTI; Evoke’s and EVERSANA’s ability to successfully drive market demand for GIMOTI; Evoke’s ability to obtain additional financing as needed to support its operations; Evoke may use its capital resources sooner than expected; warrant holders may choose not to exercise any of the outstanding warrants; Evoke’s dependence on third parties for the manufacture of GIMOTI; Evoke is entirely dependent on the success of GIMOTI; inadequate efficacy or unexpected adverse side effects relating to GIMOTI that could result in recalls or product liability claims; Evoke’s ability to maintain intellectual property protection for GIMOTI; and other risks and uncertainties detailed in Evoke’s prior press releases and in the periodic reports it files with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Evoke undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995.
Investor & Media Contact:
Daniel Kontoh-Boateng
DKB Partners
Tel: 862-213-1398
dboateng@dkbpartners.net
| Evoke Pharma, Inc. | |||||||||
| Condensed Statement of Operations | |||||||||
| (unaudited) | |||||||||
| Three Months Ended March 31, | |||||||||
| 2024 | 2023 | ||||||||
| Net product sales | $ | 1,735,490 | $ | 810,408 | |||||
| Operating expenses: | |||||||||
| Cost of goods sold | 92,529 | 50,591 | |||||||
| Research and development | 4,645 | 66,990 | |||||||
| Selling, general and administrative | 3,139,536 | 2,847,940 | |||||||
| Total operating expenses | 3,236,710 | 2,965,521 | |||||||
| Loss from operations | (1,501,220 | ) | (2,155,113 | ) | |||||
| Other income (expense): | |||||||||
| Interest income | 46,058 | 35,331 | |||||||
| Interest expense | (124,658 | ) | (123,288 | ) | |||||
| Total other expense | (78,600 | ) | (87,957 | ) | |||||
| Net loss | $ | (1,579,820 | ) | $ | (2,243,070 | ) | |||
| Net loss per share of common stock, basic and diluted | $ | (0.17 | ) | $ | (0.67 | ) | |||
| Weighted-average shares used to compute basic and diluted net loss per share | 9,082,139 | 3,343,070 | |||||||
| Evoke Pharma, Inc | |||||||||
| Condensed Balance Sheets | |||||||||
| March 31, 2024 | December 31, 2023 | ||||||||
| (unaudited) | |||||||||
| Assets | |||||||||
| Current Assets: | |||||||||
| Cash and cash equivalents | $ | 9,702,755 | $ | 4,739,426 | |||||
| Accounts receivable, net of allowance for credit losses of | 1,451,904 | 673,071 | |||||||
| Prepaid expenses | 704,215 | 885,040 | |||||||
| Inventories | 588,776 | 481,840 | |||||||
| Other current assets | 6,312 | 47,532 | |||||||
| Total current assets | 12,453,962 | 6,826,909 | |||||||
| Deferred offering costs | - | 241,637 | |||||||
| Total assets | $ | 12,453,962 | $ | 7,068,546 | |||||
| Liabilities and stockholders' equity | |||||||||
| Current Liabilities: | |||||||||
| Accounts payable and accrued expenses | $ | 1,953,959 | $ | 1,711,778 | |||||
| Accrued compensation | 265,881 | 1,324,010 | |||||||
| Note Payable | 5,000,000 | 5,000,000 | |||||||
| Accrued interest payable | 1,736,953 | 1,612,295 | |||||||
| Total current liabilities | 8,956,793 | 9,648,083 | |||||||
| Total liabilities | 8,956,793 | 9,648,083 | |||||||
| Stockholders' equity (deficit): | |||||||||
| Common stock, | 859 | 334 | |||||||
| Additional paid-in capital | 128,515,568 | 120,859,567 | |||||||
| Accumulated deficit | (125,019,258 | ) | (123,439,438 | ) | |||||
| Total stockholders' equity (deficit) | 3,497,169 | (2,579,537 | ) | ||||||
| Total liabilities and stockholders' equity (deficit) | $ | 12,453,962 | $ | 7,068,546 | |||||
FAQ
What was Evoke Pharma's net product sales in Q1 2024?
How much did Evoke Pharma's prescriber numbers grow in Q1 2024?
What is Evoke Pharma's net revenue guidance for 2024?
How much did Evoke Pharma raise through a public offering in Q1 2024?
What challenges did Evoke Pharma face in Q1 2024?
What was Evoke Pharma's net loss in Q1 2024?
What is the cash position of Evoke Pharma as of March 31, 2024?
